AR126718A1 - Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingeniería - Google Patents
Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingenieríaInfo
- Publication number
- AR126718A1 AR126718A1 ARP220102109A ARP220102109A AR126718A1 AR 126718 A1 AR126718 A1 AR 126718A1 AR P220102109 A ARP220102109 A AR P220102109A AR P220102109 A ARP220102109 A AR P220102109A AR 126718 A1 AR126718 A1 AR 126718A1
- Authority
- AR
- Argentina
- Prior art keywords
- tautomers
- pharmaceutically acceptable
- acceptable salts
- degradation
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000008684 selective degradation Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 8
- 230000015556 catabolic process Effects 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 7
- 238000006731 degradation reaction Methods 0.000 abstract 7
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 4
- 239000004475 Arginine Chemical group 0.000 abstract 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 3
- 229960003121 arginine Drugs 0.000 abstract 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 229960000310 isoleucine Drugs 0.000 abstract 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 3
- 229930182817 methionine Chemical group 0.000 abstract 3
- 229960004452 methionine Drugs 0.000 abstract 3
- 239000004471 Glycine Chemical group 0.000 abstract 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 2
- 229960002743 glutamine Drugs 0.000 abstract 2
- 229960002449 glycine Drugs 0.000 abstract 2
- 229960002885 histidine Drugs 0.000 abstract 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Chemical group OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
- 229960003136 leucine Drugs 0.000 abstract 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
- 229960005190 phenylalanine Drugs 0.000 abstract 2
- 229960004799 tryptophan Drugs 0.000 abstract 2
- 229960004295 valine Drugs 0.000 abstract 2
- 239000004474 valine Chemical group 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Chemical group 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 abstract 1
- 229940009098 aspartate Drugs 0.000 abstract 1
- 229960003646 lysine Drugs 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 229960001153 serine Drugs 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
- 229960002898 threonine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente descripción se refiere a polipéptidos diseñados por ingeniería que comprenden dominios de degradación, compuestos, composiciones y métodos para su preparación y uso en la degradación de proteínas diseñadas por ingeniería en células. Reivindicación 1: Un polipéptido diseñado por ingeniería que comprende un dominio de degradación, en donde el dominio de degradación comprende la secuencia de aminoácidos FCX¹X²CGX³X⁴ (SEC ID Nº 1), en donde: X¹ se selecciona de asparagina, aspartato, glicina, glutamina, metionina, histidina, triptófano, isoleucina, arginina, leucina, valina, treonina y fenilalanina, X² se selecciona de glutamina, arginina, histidina, leucina, fenilalanina, tirosina, triptófano, isoleucina, valina y metionina, X³ se selecciona de alanina, serina, cisteína, arginina, leucina, isoleucina, metionina y glicina, y X⁴ se selecciona de serina, metionina, lisina, isoleucina, valina, histidina, glutamina, arginina, fenilalanina y triptófano. Reivindicación 72: Un método para reducir el nivel del polipéptido diseñado por ingeniería de acuerdo con cualquiera de las reivindicaciones 1 a 61, que comprende poner en contacto el polipéptido diseñado por ingeniería con un agente de degradación seleccionado de: los compuestos del grupo de fórmula (1), y tautómeros de los mismos, y sales farmacéuticamente aceptables de los mismos, y sales farmacéuticamente aceptables de tautómeros de los mismos. Reivindicación 73: Un método para reducir el nivel de un polipéptido diseñado por ingeniería en una célula, que comprende poner en contacto la célula de acuerdo con cualquiera de las reivindicaciones 64 a 70 con un agente de degradación seleccionado de: los compuestos del grupo de fórmula (1), y tautómeros de los mismos, y sales farmacéuticamente aceptables de los mismos, y sales farmacéuticamente aceptables de tautómeros de los mismos. Reivindicación 94: El método de cualquiera de las reivindicaciones 91 a 93, en donde el agente de degradación es un compuesto seleccionado a partir de: los compuestos del grupo de fórmula (1), y tautómeros de los mismos, sales farmacéuticamente aceptables de los mismos y sales farmacéuticamente aceptables de tautómeros de los mismos. Reivindicación 95: Un compuesto seleccionado a partir de: los compuestos del grupo de fórmula (1), y tautómeros de los mismos, sales farmacéuticamente aceptables de los mismos y sales farmacéuticamente aceptables de tautómeros de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163230225P | 2021-08-06 | 2021-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126718A1 true AR126718A1 (es) | 2023-11-08 |
Family
ID=83692652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102109A AR126718A1 (es) | 2021-08-06 | 2022-08-05 | Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingeniería |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230095912A1 (es) |
| EP (1) | EP4380582A1 (es) |
| JP (1) | JP2024528988A (es) |
| KR (1) | KR20240043780A (es) |
| CN (1) | CN117794554A (es) |
| AR (1) | AR126718A1 (es) |
| AU (1) | AU2022324621A1 (es) |
| CA (1) | CA3223636A1 (es) |
| CL (1) | CL2024000305A1 (es) |
| CO (1) | CO2024001133A2 (es) |
| IL (1) | IL309653A (es) |
| MX (1) | MX2024000901A (es) |
| TW (1) | TW202321278A (es) |
| WO (1) | WO2023015283A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202304214D0 (en) * | 2023-03-23 | 2023-05-10 | Univ Oxford Innovation Ltd | System |
| WO2024201248A1 (en) * | 2023-03-24 | 2024-10-03 | Pin Therapeutics, Inc. | Compounds and methods for degrading gspt1 |
| WO2025003466A1 (en) * | 2023-06-30 | 2025-01-02 | Universitaet Heidelberg | Peptides as antagonists of ikaros zinc finger family (ikzf) proteins to activate the immune system against tumor cells |
| WO2025016359A1 (zh) * | 2023-07-14 | 2025-01-23 | 标新生物医药科技(上海)有限公司 | 戊二酰亚胺基异吲哚啉酮骨架的化合物 |
| WO2025110699A1 (ko) * | 2023-11-21 | 2025-05-30 | 주식회사 프로티어바이오텍 | 신규한 화합물 및 이의 용도 |
| KR20250169302A (ko) | 2024-03-22 | 2025-12-02 | 브리스톨-마이어스 스큅 컴퍼니 | 신규 fak 분해제 화합물 및 그의 용도 |
| CN119708220B (zh) * | 2024-12-23 | 2025-08-05 | 无锡傲锐东源生物科技有限公司 | 抗人yap1蛋白单克隆抗体及其杂交瘤细胞株和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US136A (en) | 1837-03-03 | Mode of molding candles | ||
| US5994A (en) | 1849-01-02 | Combined beading-tool and circular shears | ||
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ATE528406T1 (de) | 1999-04-29 | 2011-10-15 | Gbp Ip Llc | Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer |
| CN1352301A (zh) * | 2000-11-02 | 2002-06-05 | 上海博德基因开发有限公司 | 一种新的多肽——人二氢乳清酸酶9.46和编码这种多肽的多核苷酸 |
| KR102656934B1 (ko) | 2017-07-10 | 2024-04-16 | 셀진 코포레이션 | 항증식성 화합물 및 이의 사용 방법 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CA3079407A1 (en) * | 2017-10-18 | 2019-04-25 | Novartis Ag | Compositions and methods for selective protein degradation |
| US12049482B2 (en) * | 2017-10-31 | 2024-07-30 | The Brigham And Women's Hospital, Inc. | Molecular switch-mediated control of engineered cells |
| WO2020219742A1 (en) * | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| CN110438112B (zh) * | 2019-08-16 | 2021-09-10 | 苏州科宁多元醇有限公司 | 一种d-阿洛酮糖-3-差向异构酶的突变体及其应用 |
-
2022
- 2022-08-05 CA CA3223636A patent/CA3223636A1/en active Pending
- 2022-08-05 US US17/817,777 patent/US20230095912A1/en active Pending
- 2022-08-05 AR ARP220102109A patent/AR126718A1/es unknown
- 2022-08-05 JP JP2024506674A patent/JP2024528988A/ja active Pending
- 2022-08-05 TW TW111129489A patent/TW202321278A/zh unknown
- 2022-08-05 MX MX2024000901A patent/MX2024000901A/es unknown
- 2022-08-05 WO PCT/US2022/074589 patent/WO2023015283A1/en not_active Ceased
- 2022-08-05 KR KR1020247007065A patent/KR20240043780A/ko active Pending
- 2022-08-05 AU AU2022324621A patent/AU2022324621A1/en active Pending
- 2022-08-05 CN CN202280054544.9A patent/CN117794554A/zh active Pending
- 2022-08-05 EP EP22790152.7A patent/EP4380582A1/en active Pending
- 2022-08-05 IL IL309653A patent/IL309653A/en unknown
-
2024
- 2024-01-31 CL CL2024000305A patent/CL2024000305A1/es unknown
- 2024-02-01 CO CONC2024/0001133A patent/CO2024001133A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL309653A (en) | 2024-02-01 |
| JP2024528988A (ja) | 2024-08-01 |
| US20230095912A1 (en) | 2023-03-30 |
| CO2024001133A2 (es) | 2024-03-07 |
| EP4380582A1 (en) | 2024-06-12 |
| CA3223636A1 (en) | 2023-02-09 |
| CN117794554A (zh) | 2024-03-29 |
| TW202321278A (zh) | 2023-06-01 |
| KR20240043780A (ko) | 2024-04-03 |
| AU2022324621A1 (en) | 2024-01-18 |
| WO2023015283A1 (en) | 2023-02-09 |
| MX2024000901A (es) | 2024-02-06 |
| CL2024000305A1 (es) | 2024-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126718A1 (es) | Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingeniería | |
| RU2014120804A (ru) | Моноклональные антитела и способы их применения | |
| Morimoto et al. | Establishment and characterization of mammalian cell lines stably expressing human L-type amino acid transporters | |
| AR132933A2 (es) | Medio de cultivo celular suplementado con taurina y métodos de utilización | |
| ES2585580T3 (es) | Péptidos novedosos antienvejecimiento y composición cosmética y/o farmacéutica que los contiene | |
| RU2012151500A (ru) | Композиции и способы, пригодные для снижения вязкости белковосодержащих составов | |
| RU2014133818A (ru) | Стабилизированный состав pth | |
| CA2381229A1 (en) | Stabilized g-csf preparations | |
| AR043234A1 (es) | Metodo para reducir la formacion de acrilamida en alimentos | |
| MX381014B (es) | Uso de tripeptidil-peptidasas que toleran la prolina en composiciones de un aditivo para piensos. | |
| AR103322A1 (es) | Derivados de glucagón con estabilidad mejorada | |
| HK1204290A1 (en) | Materials and methods for treating diarrhea | |
| CL2024002086A1 (es) | Formulaciones de anticuerpos anti-il-23p19. | |
| de la Llosa et al. | On the mechanism of reversible inactivation of luteinizing hormone by urea | |
| CN104328158B (zh) | 适于动物细胞表达产品大规模生产的化学成分明确培养基 | |
| Fleisher et al. | Leucine aminopeptidase in human serum: comparison of hydrolysis of l-leucylglycine and l-leucyl-β-naphthylamide | |
| AU2002309121A1 (en) | Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field | |
| ES2607490T3 (es) | Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen | |
| Caro et al. | A combination of intracellular leucine with either glutamate or aspartate inhibits autophagic proteolysis in isolated rat hepatocytes | |
| Moat et al. | The amino acid nutrition of yeast in relationship to biotin deficiency | |
| AR114334A1 (es) | Método para reparar el cabello sometido a tratamientos oxidantes | |
| Shan et al. | Attenuated" cross talk" between κ-opioid receptors and β-adrenoceptors in the heart of chronically hypoxic rats | |
| Lederer | β-structure in acetoacetate decarboxylase | |
| AR108969A1 (es) | Derivado de glucagón, un conjugado del mismo, y una composición que comprende el mismo, y un uso terapéutico del mismo | |
| JP2022548776A (ja) | ヒト人工多能性幹細胞のための費用効果の高い培地およびプロトコル |